E8LA Stock Overview
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GeoVax Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$10.30 |
| 52 Week Low | US$0.20 |
| Beta | 2.92 |
| 1 Month Change | 0% |
| 3 Month Change | -93.89% |
| 1 Year Change | -97.57% |
| 3 Year Change | -99.67% |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| E8LA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | 1.7% |
| 1Y | -97.6% | -23.0% | 2.3% |
Return vs Industry: E8LA underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: E8LA underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| E8LA volatility | |
|---|---|
| E8LA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E8LA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine E8LA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 17 | David Dodd | www.geovax.com |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
GeoVax Labs, Inc. Fundamentals Summary
| E8LA fundamental statistics | |
|---|---|
| Market cap | €3.32m |
| Earnings (TTM) | -€24.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs E8LA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E8LA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$291.09k |
| Gross Profit | -US$291.09k |
| Other Expenses | US$25.68m |
| Earnings | -US$25.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did E8LA perform over the long term?
See historical performance and comparison